E-cigarettes are commonly used in attempts to stop smoking, but evidence is limited regarding their effectiveness as compared with that of nicotine products approved as smoking-cessation treatments.
Background Access to mobile phones continues to increase exponentially globally, outstripping access to fixed telephone lines, fixed computers and the Internet. Mobile phones are an appropriate and effective option for the delivery of smoking cessation support in some contexts. This review updates the evidence on the effectiveness of mobile phone‐based smoking cessation interventions. Objectives To determine whether mobile phone‐based smoking cessation interventions increase smoking cessation in people who smoke and want to quit. Search methods For the most recent update, we searched the Cochrane Tobacco Addiction Group Specialised Register in April 2015. We also searched the UK Clinical Research Network Portfolio for current projects in the UK, and the ClinicalTrials.gov register for ongoing or recently completed studies. We searched through the reference lists of identified studies and attempted to contact the authors of ongoing studies. We applied no restrictions on language or publication date. Selection criteria We included randomised or quasi‐randomised trials. Participants were smokers of any age who wanted to quit. Studies were those examining any type of mobile phone‐based intervention for smoking cessation. This included any intervention aimed at mobile phone users, based around delivery via mobile phone, and using any functions or applications that can be used or sent via a mobile phone. Data collection and analysis Review authors extracted information on risk of bias and methodological details using a standardised form. We considered participants who dropped out of the trials or were lost to follow‐up to be smoking. We calculated risk ratios (RR) and 95% confidence intervals (CI) for each included study. Meta‐analysis of the included studies used the Mantel‐Haenszel fixed‐effect method. Where meta‐analysis was not possible, we presented a narrative summary and descriptive statistics. Main results This updated search identified 12 studies with six‐month smoking cessation outcomes, including seven studies completed since the previous review. The interventions were predominantly text messaging‐based, although several paired text messaging with in‐person visits or initial assessments. Two studies gave pre‐paid mobile phones to low‐income human immunodeficiency virus (HIV)‐positive populations ‐ one solely for phone counselling, the other also included text messaging. One study used text messages to link to video messages. Control programmes varied widely. Studies were pooled according to outcomes ‐ some providing measures of continuous abstinence or repeated measures of point prevalence; others only providing 7‐day point prevalence abstinence. All 12 studies pooled using their most rigorous 26‐week measures of abstinence provided an RR of 1.67 (95% CI 1.46 to 1.90; I2 = 59%). Six studies verified quitting biochemically at six months (RR 1.83; 95% CI 1.54 to 2.19). Authors' conclusions The current evidence supports a beneficial impact of mobile phone‐based smoking cessation interventions on six‐month cessation outcomes. While all studies were good quality, the fact that those studies with biochemical verification of quitting status demonstrated an even higher chance of quitting further supports the positive findings. However, it should be noted that most included studies were of text message interventions in high‐income countries with good tobacco control policies. Therefore, caution should be taken in generalising these results outside of this type of intervention and context.
Aims: We reviewed available research on the use, content and safety of electronic cigarettes (EC), and on their effects on users, to assess their potential for harm or benefit and to extract evidence that can guide future policy.Methods: Studies were identified by systematic database searches and screening references to February 2014.Results: EC aerosol can contain some of the toxicants present in tobacco smoke, but at levels which are much lower. Long‐term health effects of EC use are unknown but compared with cigarettes, EC are likely to be much less, if at all, harmful to users or bystanders. EC are increasingly popular among smokers, but to date there is no evidence of regular use by never‐smokers or by non‐smoking children. EC enable some users to reduce or quit smoking.Conclusions: Allowing EC to compete with cigarettes in the market‐place might decrease smoking‐related morbidity and mortality. Regulating EC as strictly as cigarettes, or even more strictly as some regulators propose, is not warranted on current evidence. Health professionals may consider advising smokers unable or unwilling to quit through other routes to switch to EC as a safer alternative to smoking and a possible pathway to complete cessation of nicotine use.
Objectives To measure the short-term effects of an electronic nicotine delivery device (“e cigarette”, ENDD) on desire to smoke, withdrawal symptoms, acceptability, pharmacokinetic properties and adverse effects. Design Single blind randomised repeated measures cross-over trial of the Ruyan V8 ENDD. Setting University research centre in Auckland, New Zealand. Participants 40 adult dependent smokers of 10 or more cigarettes per day. Interventions Participants were randomised to use ENDDs containing 16 mg nicotine or 0 mg capsules, Nicorette nicotine inhalator or their usual cigarette on each of four study days 3 days apart, with overnight smoking abstinence before use of each product. Main outcome measures The primary outcome was change in desire to smoke, measured as “area under the curve” on an 11-point visual analogue scale before and at intervals over 1 h of use. Secondary outcomes included withdrawal symptoms, acceptability and adverse events. In nine participants, serum nicotine levels were also measured. Results Over 60 min, participants using 16 mg ENDD recorded 0.82 units less desire to smoke than the placebo ENDD (p=0.006). No difference in desire to smoke was found between 16 mg ENDD and inhalator. ENDDs were more pleasant to use than inhalator (p=0.016) and produced less irritation of mouth and throat (p<0.001). On average, the ENDD increased serum nicotine to a peak of 1.3 mg/ml in 19.6 min, the inhalator to 2.1 ng/ml in 32 min and cigarettes to 13.4 ng/ml in 14.3 min. Conclusions The 16 mg Ruyan V8 ENDD alleviated desire to smoke after overnight abstinence, was well tolerated and had a pharmacokinetic profile more like the Nicorette inhalator than a tobacco cigarette. Evaluation of the ENDD for longer-term safety, potential for long-term use and efficacy as a cessation aid is needed. Trial registration No.12607000587404, Australia and New Zealand Clinical Trials Register
22 October 2019 in Cochrane Database of Systematic Reviews